An important update for ACE patients using Palforzia

An important update for ACE patients using Palforzia

Following a recent announcement from the manufacturer, Stallergenes, regarding the planned discontinuation of Palforzia in the UK, we want to take a moment to reassure all patients and families currently receiving care with us.

Our priority is, and always will be, your child’s safety, continuity of care, and your confidence in the treatment journey.

Below, we’ve outlined exactly what this update means for you.

Patients due to start Palforzia

If your child is scheduled to begin Palforzia treatment with ACE, your programme will continue as planned. Stock of the initial dose escalation packs will remain available until 31 March 2026, allowing new starters to commence treatment as expected.

Patients currently receiving Palforzia

If your child is already on Palforzia and is in the up-dosing or maintenance phase, treatment can continue as normal. Supplies for these stages will remain available until 31 March 2027, ensuring there is sufficient time for ongoing treatment and careful clinical planning.

Why is Palforzia being discontinued in the UK?

The manufacturer has confirmed that this decision is not related to the safety, quality, or effectiveness of Palforzia. Instead, it has been made for strategic and operational reasons.

To minimise disruption to patient care, the withdrawal will take place gradually across the UK:

• 31 March 2026 – discontinuation of the initial dose escalation packs

• 31 March 2027 – discontinuation of up-dosing (Levels 1–11) and maintenance packs

This phased approach allows families and clinicians the time and space needed to plan next steps thoughtfully and safely.

Our commitment to you

Our clinical team is actively reviewing treatment plans where required and will continue to support every patient throughout this transition period. You will not be navigating this alone. We are here to answer questions, provide clarity, and ensure that care remains uninterrupted.

If you have any concerns or would like to discuss your child’s individual treatment plan, please don’t hesitate to get in touch with us at office@oit.clinic.

Your care, safety, and confidence remain at the heart of everything we do.